News | Heart Valve Technology | October 03, 2018

Prosthetic Valve Mismatches Common in TAVR Procedures

In largest study to date, severe cases of prosthesis-patient mismatch were associated with higher risk of death and hospital readmissions

Prosthetic Valve Mismatches Common in TAVR Procedures

October 3, 2018 — A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and moderate cases of prosthesis-patient mismatch (PPM), meaning the implanted heart valve is too small for the patient, which can lead to inadequate blood flow. The research team from Penn Medicine also found that the risk of death and of heart failure readmissions were 19 percent and 12 percent higher, respectively, after one year as compared to patients without severe PPM.

Results of the study were presented as a late-breaking abstract at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 meeting, Sept. 21-25 in San Diego, and simultaneously published online in the Journal of the American College of Cardiology.[1]

“This is an important contemporary snapshot of what’s happening in the real world with commercial TAVR procedures,” said the study’s lead author Howard C. Herrmann, M.D., FACC, MSCAI, the John W. Bryfogle Professor of Cardiovascular Medicine and Surgery at Penn’s Perelman School of Medicine and director of Penn Medicine’s Interventional Cardiology Program, who presented the results at TCT. “This is the first study that is large enough to demonstrate meaningful data associated with PPM for a relatively new procedure like TAVR. Based on these findings, PPM is an important problem in this population, one that deserves greater awareness among operators. And being aware of it is the first step in trying to prevent it.”

TAVR was approved by the U.S. Food and Drug Administration (FDA) in 2011 for the treatment of aortic stenosis, a narrowing of the heart’s aortic valve. It has revolutionized valve replacement options for patients with this disease who are too sick or too high risk for surgical (open-heart) valve replacement (SAVR). This minimally invasive, catheter-based approach allows physicians to replace the aortic valve without need to remove the old, damaged one.

Of the 62,125 patients who received TAVR in the United States between 2014 and 2017 and who were evaluated, researchers found 12 percent experienced severe PPM, while 25 percent had moderate PPM. Researchers collected and analyzed patient data from the U.S. STS/ACC Transcatheter Valve Therapy (TVT) Registry, which tracks all commercial procedures performed in the United States. To further study patient outcomes, the authors linked patients in the U.S. STS/ACC TVT registry to Centers for Medicare & Medicaid Services’ administrative claims data for 37,470 of their patients. After 30 days, patients with severe PPM had higher rates of heart failure hospitalization, stroke, and death.

Historically, PPM has been associated with worse outcomes after SAVR, however, less has been known about the incidence, outcomes and predictors of PPM in TAVR patients. Past studies have been small, with limited follow up, and some from single centers — combined, they only represent 4,000 patients — and measurement techniques for the valve opening have been inconsistent.

PPM is a mismatch of the blood flow dynamics of the prosthetic valve and the amount of blood the heart needs to pump to the rest of the patient’s body. For example, having too small of a valve in a person with a large body surface area (height and weight) affects their ability to get enough blood flow when they exercise. In previous studies, severe PPM in both SAVR and TAVR patients have been associated with higher risk of death and hospital readmission, decreased exercise abilities and a higher rate of valve deterioration over time.

The authors identified several predictors of PPM, including patients with a smaller valve prosthesis, those who had a larger body surface area, or patients who are female or younger.

“Severe PPM occurs frequently after TAVR procedures, and it results in worse outcomes, even after a short period of one year,” Herrmann said. “Now that we’re more aware of this, we need to look at strategies and compare devices and techniques in future studies to determine what will help us best limit this risk or avoid it in the future.”

Co-authors of the study include Nimesh D. Desai M.D., FACC, of Penn’s Perelman School of Medicine; Samuel A. Daneshvar, M.D., FACC, and Gregg C. Fonarow M.D., FACC, of the University of California, Los Angeles; Amanda Stebbins, Sreekanth Vemulapalli, M.D., FACC, Jennifer Rymer, M.D.,, and Andrzej S. Kosinski, Ph.D., of the Duke Clinical Research Institute; David J. Malenka, M.D., FACC, of Dartmouth-Hitchock; and Vinod H. Thourani, M.D., FACC, of MedStar Heart and Vascular Institute and Georgetown University.

For more information: www.onlinejacc.org

 

Links to TCT 2018 Late-breaking Cardiovascular Clinical Trials, News and Videos

 

Reference

1. Herrmann H.C., Daneshvar S.A., Fonarow G.C., et al. Prosthesis–Patient Mismatch in 62,125 Patients Following Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, Sept. 3, 2018. DOI: 10.1016/j.jacc.2018.09.001

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init